Literature DB >> 1649271

Histological grading and bromodeoxyuridine labeling index of astrocytomas. Comparative study in a series of 60 cases.

F Labrousse1, C Daumas-Duport, L Batorski, T Hoshino.   

Abstract

The histological grade and the bromodeoxyuridine (BUdR) labeling index of 60 astrocytomas of "ordinary" cell types (fibrillary, protoplasmic, gemistocytic, and anaplastic astrocytomas and glioblastomas) were compared to determine whether the grading system reflects the proliferative potential of the tumors. The tumor grade was based on the presence or absence of four criteria (nuclear abnormalities, mitosis, necrosis, and vascular endothelial proliferation): Grade 1, no criterion, Grade 2, one criterion, Grade 3, two criteria; and Grade 4, three or four criteria. The BUdR labeling index, or percentage of S-phase cells, was calculated in paraffin-embedded tumor sections after in situ labeling by intraoperative intravenous infusion of BUdR, 200 mg/sq m. Exponential regression analyses showed a positive correlation between the histological grade and labeling index (r = 0.88, p less than 0.001) that was stronger than the correlations between log labeling index and age (r = 0.55, p less than 0.001) and between grade and age (r = 0.55, p less than 0.001). These results indicate that the histological grading system reflects the proliferative potential of "ordinary" astrocytomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649271     DOI: 10.3171/jns.1991.75.2.0202

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

Review 1.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

2.  Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children.

Authors:  T Czech; I Slavc; M Aichholzer; C Haberler; W Dietrich; K Dieckmann; W Koos; H Budka
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

Review 3.  The role of surgery in low grade gliomas.

Authors:  J Bampoe; M Bernstein
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

Review 4.  Recognition and management of gliomas.

Authors:  S E Kaba; A P Kyritsis
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

5.  PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade.

Authors:  Fazilet Kayaselçuk; Suzan Zorludemir; Derya Gümürdühü; Handan Zeren; Tahsin Erman
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

Review 6.  The application of 5-bromodeoxyuridine in the management of CNS tumors.

Authors:  A Freese; D O'Rourke; K Judy; M J O'Connor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms.

Authors:  E Karamitopoulou; E Perentes; M Melachrinou; T Maraziotis
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  Proliferative potential and prognostic evaluation of low-grade astrocytomas.

Authors:  S Ito; K L Chandler; M D Prados; K Lamborn; J Wynne; M K Malec; C B Wilson; R L Davis; T Hoshino
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.

Authors:  E Karamitopoulou; E Perentes; I Diamantis; T Maraziotis
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  The level of MnSOD is directly correlated with grade of brain tumours of neuroepithelial origin.

Authors:  M Landriscina; F Remiddi; F Ria; B Palazzotti; M E De Leo; M Iacoangeli; R Rosselli; M Scerrati; T Galeotti
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.